EP13.03: First Report of Use of Mifepristone in Severe Pulmonary Arterial Hypertension (PAH) for Medical Termination (MT)

Ultrasound in Obstetrics and Gynecology - United States
doi 10.1002/uog.19994
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Development of a New Patient-Reported Outcome (PRO) Instrument for Pulmonary Arterial Hypertension (PAH): The Pulmonary Arterial Hypertension–symptoms and Impact (PAH-SYMPACT) Questionnaire

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Withdrawal of Long-Term Epoprostenol Therapy in Pulmonary Arterial Hypertension (PAH)

Pulmonary Circulation
PulmonaryRespiratory Medicine
2017English

P2 In-Flight Hypoxaemia in Patients With Pulmonary Arterial Hypertension (PAH)

Thorax
PulmonaryRespiratory Medicine
2011English

Pharmacokinetics of Ambrisentan, a Novel Drug for Treatment of Pulmonary Arterial Hypertension (PAH), in Japanese Subjects

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2010English

Staging Treatment of Atrial Septal Defect With Severe Pulmonary Arterial Hypertension: Case Report

Surgery & Case Studies: Open Access Journal
2019English

Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension

Circulation Journal
MedicineCardiovascular MedicineCardiology
2012English

Effects of Inhaled Aviptadil (Vasoactive Intestinal Peptide) in Patients With Pulmonary Arterial Hypertension (PAH)

2010English

Successful Titration of Triple Oral Therapy in a Patient With Pulmonary Arterial Hypertension (PAH)

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2017English

Domicilliary Use of Oral Mifepristone and Misoprostol in First Trimester Medical Abortion

Journal of Medical Science And clinical Research
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy